Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon beta 1a inhalation - Synairgen

Drug Profile

Interferon beta 1a inhalation - Synairgen

Alternative Names: AZD-9412; SNG-001

Latest Information Update: 26 Jun 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Southampton
  • Developer Synairgen
  • Class Antineoplastics; Interferons
  • Mechanism of Action Immunostimulants; Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease
  • No development reported Influenza virus infections
  • Discontinued Asthma

Most Recent Events

  • 07 Feb 2018 Synairgen initiates a phase II trial for Chronic obstructive pulmonary disease (COPD) in United Kingdom (Inhalation)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Influenza-virus-infections in United Kingdom (Inhalation, Aerosol)
  • 27 Sep 2017 Synairgen plans a clinical trial for Chronic obstructive pulmonary disease in winter of 2017/2018, for which regulatory application is being submitted
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top